Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0RKJCI
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
HER2 targeted DEP conjugate
|
|||||
| Synonyms |
HER 2 Targeted DEP conjugate (Starpharma)
Click to Show/Hide
|
|||||
| Organization |
Starpharma Holdings Ltd.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 1 Indication(s)
Epithelial ovarian cancer [ICD11:2B5D]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
13
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Active metabolite of irinotecan SN38
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
HER2-targeted DEP.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.